Developer docs
API playgroundTry for free, no card

Search company profiles

Arctoris

Full company profile

uuid0000zz5

Namestring
Arctoris
Legal namestring
Arctoris Limited
Websiteurl
arctoris.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Arctoris is a UK-based Partnership Research Organisation (PRO) founded in 2018 out of the University of Oxford, providing automated wet lab biology R&D and data generation services to biotech, techbio, and pharmaceutical companies. The company's core offering is the Ulysses® platform — a fully robotic, cloud-controlled drug discovery platform that executes entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, capturing every action, parameter, and datapoint in real time. This platform generates AI/ML-ready, FAIR-compliant structured datasets with up to 100x more datapoints per assay than industry standard, compressing Design-Make-Test-Analyse (DMTA) cycles from weeks to days.

The company monetises through bespoke, multi-year partnership agreements spanning target identification through IND-enabling studies, plus a distinct Foundation Model Data Generation revenue stream serving AI drug discovery labs (including Isomorphic Labs, where Arctoris delivered >2.2M annotated datapoints across 65 targets). Arctoris pursues a direct enterprise field sales motion, working as an extension of partner R&D teams. Customer segments include biotech companies, techbio/AI drug discovery firms, pharmaceutical companies, and increasingly AI foundation model developers. Operations span offices in Oxford (UK headquarters with primary laboratory at 120E Olympic Avenue, Abingdon), Boston (US), and Singapore (APAC hub), with partnership relationships across the US, UK, Germany, Australia, Korea, and China. Key technical metrics include Z' scores consistently above 0.75, assay onboarding in as little as 4 hours, >100 proteins produced with >95% purity, and 12+ biologics guided to IND.

Short descriptiontext

Arctoris is a UK-based Partnership Research Organisation operating the Ulysses® fully robotic, cloud-controlled drug discovery platform, generating AI-ready experimental data for biotech, techbio, pharma, and AI foundation model developers across global markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAbingdon, United Kingdom
HQ citystring
Abingdon
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, robotic lab automation, contract research organization, AI-ready data generation, biotech research partnership
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership Research Services
TypeProfessional Services
Description

Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio and pharma companies. Services span from target identification through IND-enabling studies, generating revenue through project-based and long-term partnership agreements.

arctoris.com
2Foundation Model Data Generation
TypeData Monetisation
Description

Custom experimental campaigns for AI model training specifically designed to fill gaps in proprietary model knowledge graphs, with data ownership transferred to clients as strategic assets.

arctoris.com
3Bespoke Proprietary Training Datasets
TypeProfessional Services
Description

Custom experimental campaigns—chemistry, biology or biophysics—specifically designed to fill gaps in model knowledge graphs. Clients own resulting datasets outright as proprietary strategic assets.

arctoris.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Bespoke Partnership Research Services
ModelOtherBilling cadenceMulti-year contract
Notes

Services tailored to specific partner needs across the drug discovery pipeline, from target validation to IND-enabling studies. No standard pricing tiers publicly available.

arctoris.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Ulysses®
Description

Arctoris' fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology

arctoris.com
Core offering1 text field

Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies. The core offering is delivered through Ulysses®, a fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating precise, reproducible, and AI-ready datasets at industrial scale. Services span from target identification through IND-enabling studies via long-term partnership agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Z' scores consistently above 0.75 in high-throughput screens; Z' values of 0.8 and higher regularly achieved in closed-loop studies
+6 more records
Product overview1 text field

Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D services. The core offering is the Ulysses® platform, a fully robotic, cloud-controlled discovery platform that executes assay cascades across biochemistry, biophysics, cell biology, and structural biology. This platform is complemented by specialized service modules including Hit Identification, Hit-to-Lead, Lead Optimization, and IND-Enabling Studies, along with Foundation Model Data Generation for AI/ML training. Additional capabilities include Biologics, Protein Science, and a recently launched Biophysics Centre of Excellence providing tenfold expanded biophysical instrumentation capacity. The company generates precise, reproducible, AI-ready datasets at scale for biotech, techbio, and pharma partners.

Product and service14 records
1Ulysses® Platform
CategoryCore platform
Description

Fully robotic, cloud-controlled drug discovery platform that executes assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating AI-ready datasets with zero human variability through industrial automation; marketed as the world's first fully automated drug discovery platform.

2Hit Identification
CategoryDrug discovery pipeline service
Description

Fully automated high-throughput screening workflows for rapid identification of high-quality chemical matter from compound libraries, delivered as a partnership research service.

3Hit-to-Lead
CategoryDrug discovery pipeline service
Description

Deep interrogation of hits through biophysical and cellular assays to identify and prioritize true leads with precision kinetic and thermodynamic characterization, delivered as a partnership research service.

4Lead Optimization
CategoryDrug discovery pipeline service
Description

Integrated multimodal workflows optimizing efficacy, safety, and developability with mechanistic profiling across concentration ranges; reduces lead optimization timelines by up to 30%.

5IND-Enabling Studies Support
CategoryDrug discovery pipeline service
Description

Comprehensive preclinical support including functional characterization, PK/PD studies, GMP-adjacent protein production, and regulatory planning; supported 12+ IND filings.

6Foundation Model Data Generation
CategoryAI data generation service
Description

High-fidelity dataset generation service for training and fine-tuning AI foundation models; delivered over 2.2M annotated datapoints for Isomorphic Labs across 65 targets with datasets outperforming CRO and public data benchmarks.

7Cell Biology Services
CategoryDiscovery capability service
Description

Comprehensive cell-based assays including target engagement, phenotypic screening, high-content imaging, and flow cytometry; supports patient-derived models and 3D cultures for predictive drug discovery.

8Biochemistry & Enzymology Services
CategoryDiscovery capability service
Description

High-throughput biochemical assays, enzymatic profiling, and kinetic analysis; delivers Z' scores above 0.75 consistently, with capacity for 2,000+ compounds per day throughput.

9Biophysics Services
CategoryDiscovery capability service
Description

Quantitative analysis of protein-ligand interactions including SPR, ITC, and thermodynamic profiling; enables high-throughput kinetic characterization across large compound libraries.

10Structural Biology Services
CategoryDiscovery capability service
Description

High-throughput X-ray crystallography, cryo-EM, and computational modeling; solved over 200 protein-ligand complex structures with processing capacity for 300+ ligands.

11Protein Science Services
CategoryDiscovery capability service
Description

Recombinant protein expression, purification, and characterization across multiple host systems (E. coli, insect, mammalian); produced over 100 proteins with purity exceeding 95%.

12Biologics Services
CategoryDiscovery capability service
Description

Antibody discovery, engineering, and functional characterization for biologics including bispecifics, peptides, and RNA therapeutics; guided over 12 biologic candidates into clinical trials.

13Data Science & Informatics
CategoryData and informatics service
Description

Integrated analytics platform providing real-time QC, kinetic modeling, curve fitting (IC50, EC50, Kd), and ML model training support; delivers FAIR-compliant, AI/ML-ready structured datasets.

14Biophysics Centre of Excellence
CategoryBiophysics capability centre
Description

Major infrastructure expansion providing tenfold increase in biophysical instrumentation capacity, addressing bottlenecks in experimental validation for AI-driven drug discovery.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-01
Description

Collaboration integrating MERCURIUS 1536 DRUG-seq whole-transcriptome profiling with Arctoris' automated workflows. Supports upstream cell preparation, compound dosing, and sample preparation in 1536-well format for scalable phenotypic screening.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Breakthrough collaboration validating first de novo protein from MP4 platform that binds ATP for heart failure treatment. Arctoris used Ulysses automation platform for protein expression, purification, and biophysical validation confirming folding, purity, and ATP-binding activity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Research collaboration demonstrating AI systems can actively generate therapeutic hypotheses. AI identified combinations of non-cancer drugs targeting breast cancer cells; Arctoris provided automated experimental validation creating closed-loop system with Z' values of 0.8+.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

AI drug discovery partnership combining Arctoris' wet lab data generation with Evariste's ML-enabled molecular design. Progressed from target selection to several qualified lead series in non-small cell lung cancer within six months.

5Isomorphic Labs
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Foundation model data generation partnership (Project Tiger). Delivered >2.2M annotated datapoints over 65 targets for training generative drug design models. Datasets yielded significantly superior model performance vs CRO and public data, underpinning clinical candidates progressing in 2025.

arctoris.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Innovate UK-backed project combining AI, machine learning and automated biology for lung cancer drug discovery targeting KRAS signalling pathway. Intelligent OMICS provides in silico target identification; Arctoris runs biological assay validation using automated platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Partner in Innovate UK-backed lung cancer project contributing cheminformatics expertise to identify appropriate chemical tools and leads for newly uncovered targets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration advancing fully autonomous closed-loop molecular discovery targeting Janus kinase (JAK) proteins. Integrates computational molecular design, automated synthesis, and experimental testing into continuous DMTA cycle. Arctoris' Ulysses platform combined with IBM's automated small molecule synthesis capabilities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration combining Arctoris' automated laboratory infrastructure with Molecule's open-source software platform for drug intellectual property sharing. Aims to reduce legal and financial barriers in collaborative drug discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Technology partnership for AI-guided drug discovery against COVID-19, spanning target identification and generative chemistry. Insilico's AI capabilities combined with Arctoris' robotic platform for rapid evaluation of novel JAK inhibitors. Partnership extended through BioTarget Cancer Research UK initiative for oncology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cloud-based automated laboratory platform enabling remote-controlled experiments for drug discovery. Operates a similar partnership model providing automated wet-lab data generation services to biotech and pharma customers.

TypeDirect peer
Description

Cloud-controlled, fully automated laboratory facility providing remote experimental execution and data generation services. Directly comparable to Arctoris's Ulysses platform in terms of robotic lab infrastructure and service delivery model.

TypeBroad incumbent
Description

AI-driven drug discovery company combining high-throughput biology with ML for pharma partnerships. Comparable as an AI drug discovery peer, though significantly larger and with in-house automated lab capabilities rather than pure service model.

TypeBroad incumbent
Description

Machine learning-driven drug discovery company combining proprietary data generation with ML models for pharma partnerships. Comparable as an AI drug discovery peer with experimental data generation capabilities and pharma partnership model.

TypeEmerging player
Description

Machine learning-driven antibody discovery company using automated laboratory robotics. Comparable as a UK-based ML-driven biotech using automation, though focused specifically on biologics rather than small molecules and services.

6Culture Biosciences
TypeEmerging player
Description

Cloud-based bioprocess development platform providing automated fermentation and cell culture services. Comparable as a cloud-lab automated services provider, though focused on bioprocess rather than drug discovery.

TypeEmerging player
Description

Cloud-based laboratory automation platform enabling experimental design and execution for life science R&D. Comparable as a lab automation platform serving biotech R&D, though focused on software infrastructure rather than full-service execution.

TypeBroad incumbent
Description

Cloud-based life sciences R&D platform providing informatics and data management for biotech R&D. Adjacent peer providing laboratory informatics infrastructure, though focused on software rather than automated experimental execution.

TypeBroad incumbent
Description

Computational drug discovery platform combining physics-based simulation with ML for pharma partnerships. Comparable as a technology-enabled drug discovery company serving pharma, though primarily computational rather than experimental automation.

TypeDirect peer
Description

AI-driven drug discovery company combining generative AI with experimental validation. Comparable as a direct customer/partner of Arctoris with overlapping AI drug discovery mission and partnership-based commercial model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability13 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arctoris

Drug Discovery Servicesarctoris.com

Arctoris is a UK-based Partnership Research Organisation operating the Ulysses® fully robotic, cloud-controlled drug discovery platform, generating AI-ready experimental data for biotech, techbio, pharma, and AI foundation model developers across global markets.

What Arctoris does

Arctoris is a UK-based Partnership Research Organisation (PRO) founded in 2018 out of the University of Oxford, providing automated wet lab biology R&D and data generation services to biotech, techbio, and pharmaceutical companies. The company's core offering is the Ulysses® platform — a fully robotic, cloud-controlled drug discovery platform that executes entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, capturing every action, parameter, and datapoint in real time. This platform generates AI/ML-ready, FAIR-compliant structured datasets with up to 100x more datapoints per assay than industry standard, compressing Design-Make-Test-Analyse (DMTA) cycles from weeks to days.

The company monetises through bespoke, multi-year partnership agreements spanning target identification through IND-enabling studies, plus a distinct Foundation Model Data Generation revenue stream serving AI drug discovery labs (including Isomorphic Labs, where Arctoris delivered >2.2M annotated datapoints across 65 targets). Arctoris pursues a direct enterprise field sales motion, working as an extension of partner R&D teams. Customer segments include biotech companies, techbio/AI drug discovery firms, pharmaceutical companies, and increasingly AI foundation model developers. Operations span offices in Oxford (UK headquarters with primary laboratory at 120E Olympic Avenue, Abingdon), Boston (US), and Singapore (APAC hub), with partnership relationships across the US, UK, Germany, Australia, Korea, and China. Key technical metrics include Z' scores consistently above 0.75, assay onboarding in as little as 4 hours, >100 proteins produced with >95% purity, and 12+ biologics guided to IND.

Arctoris firmographics

Firmographics
Name
Arctoris
Legal name
Arctoris Limited
Website
https://arctoris.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Arctoris is a UK-based Partnership Research Organisation operating the Ulysses® fully robotic, cloud-controlled drug discovery platform, generating AI-ready experimental data for biotech, techbio, pharma, and AI foundation model developers across global markets.
Ownership category
akta.pro rank

Arctoris industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Drug discovery services
  • Robotic lab automation
  • Contract research organization
  • AI-ready data generation
  • Biotech research partnership

Where Arctoris is headquartered

Location

Headquarters

HQ city
Abingdon
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Arctoris business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Partnership Research Services: Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio and pharma companies. Services span from target identification through IND-enabling studies, generating revenue through project-based and long-term partnership agreements.
  2. Foundation Model Data Generation: Custom experimental campaigns for AI model training specifically designed to fill gaps in proprietary model knowledge graphs, with data ownership transferred to clients as strategic assets.
  3. Bespoke Proprietary Training Datasets: Custom experimental campaigns—chemistry, biology or biophysics—specifically designed to fill gaps in model knowledge graphs. Clients own resulting datasets outright as proprietary strategic assets.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractBespoke Partnership Research Services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Arctoris product offering

Product offering

Core offering

Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies. The core offering is delivered through Ulysses®, a fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating precise, reproducible, and AI-ready datasets at industrial scale. Services span from target identification through IND-enabling studies via long-term partnership agreements.

Product overview

Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D services. The core offering is the Ulysses® platform, a fully robotic, cloud-controlled discovery platform that executes assay cascades across biochemistry, biophysics, cell biology, and structural biology. This platform is complemented by specialized service modules including Hit Identification, Hit-to-Lead, Lead Optimization, and IND-Enabling Studies, along with Foundation Model Data Generation for AI/ML training. Additional capabilities include Biologics, Protein Science, and a recently launched Biophysics Centre of Excellence providing tenfold expanded biophysical instrumentation capacity. The company generates precise, reproducible, AI-ready datasets at scale for biotech, techbio, and pharma partners.

Differentiator

Problem solved

Functional benefit

Brands

  • Ulysses®: Arctoris' fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology

Products and services

  • Ulysses® Platform Fully robotic, cloud-controlled drug discovery platform that executes assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating AI-ready datasets with zero human variability through industrial automation; marketed as the world's first fully automated drug discovery platform.
  • Hit Identification Fully automated high-throughput screening workflows for rapid identification of high-quality chemical matter from compound libraries, delivered as a partnership research service.
  • Hit-to-Lead Deep interrogation of hits through biophysical and cellular assays to identify and prioritize true leads with precision kinetic and thermodynamic characterization, delivered as a partnership research service.
  • Lead Optimization Integrated multimodal workflows optimizing efficacy, safety, and developability with mechanistic profiling across concentration ranges; reduces lead optimization timelines by up to 30%.
  • IND-Enabling Studies Support Comprehensive preclinical support including functional characterization, PK/PD studies, GMP-adjacent protein production, and regulatory planning; supported 12+ IND filings.
  • Foundation Model Data Generation High-fidelity dataset generation service for training and fine-tuning AI foundation models; delivered over 2.2M annotated datapoints for Isomorphic Labs across 65 targets with datasets outperforming CRO and public data benchmarks.
  • Cell Biology Services Comprehensive cell-based assays including target engagement, phenotypic screening, high-content imaging, and flow cytometry; supports patient-derived models and 3D cultures for predictive drug discovery.
  • Biochemistry & Enzymology Services High-throughput biochemical assays, enzymatic profiling, and kinetic analysis; delivers Z' scores above 0.75 consistently, with capacity for 2,000+ compounds per day throughput.
  • Biophysics Services Quantitative analysis of protein-ligand interactions including SPR, ITC, and thermodynamic profiling; enables high-throughput kinetic characterization across large compound libraries.
  • Structural Biology Services High-throughput X-ray crystallography, cryo-EM, and computational modeling; solved over 200 protein-ligand complex structures with processing capacity for 300+ ligands.
  • Protein Science Services Recombinant protein expression, purification, and characterization across multiple host systems (E. coli, insect, mammalian); produced over 100 proteins with purity exceeding 95%.
  • Biologics Services Antibody discovery, engineering, and functional characterization for biologics including bispecifics, peptides, and RNA therapeutics; guided over 12 biologic candidates into clinical trials.
  • Data Science & Informatics Integrated analytics platform providing real-time QC, kinetic modeling, curve fitting (IC50, EC50, Kd), and ML model training support; delivers FAIR-compliant, AI/ML-ready structured datasets.
  • Biophysics Centre of Excellence Major infrastructure expansion providing tenfold increase in biophysical instrumentation capacity, addressing bottlenecks in experimental validation for AI-driven drug discovery.

Quantifiable outcome

  • Z' scores consistently above 0.75 in high-throughput screens; Z' values of 0.8 and higher regularly achieved in closed-loop studies
  • +6 more outcomes

Companies that use Arctoris

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Arctoris technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability13 records

Feature7 records

Arctoris partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Alithea GenomicscoreTechnology or Integration · 1 January 2026Collaboration integrating MERCURIUS 1536 DRUG-seq whole-transcriptome profiling with Arctoris' automated workflows. Supports upstream cell preparation, compound dosing, and sample preparation in 1536-well format for scalable phenotypic screening.
  • 310.aicoreStrategic or Co-development Partner · 1 January 2025Breakthrough collaboration validating first de novo protein from MP4 platform that binds ATP for heart failure treatment. Arctoris used Ulysses automation platform for protein expression, purification, and biophysical validation confirming folding, purity, and ATP-binding activity.
  • University of Cambridge and King's College LondoncoreStrategic or Co-development Partner · 1 January 2024Research collaboration demonstrating AI systems can actively generate therapeutic hypotheses. AI identified combinations of non-cancer drugs targeting breast cancer cells; Arctoris provided automated experimental validation creating closed-loop system with Z' values of 0.8+.
  • Evariste TechnologiescoreStrategic or Co-development Partner · 1 January 2024AI drug discovery partnership combining Arctoris' wet lab data generation with Evariste's ML-enabled molecular design. Progressed from target selection to several qualified lead series in non-small cell lung cancer within six months.
  • Isomorphic LabscoreStrategic or Co-development Partner · 1 January 2024Foundation model data generation partnership (Project Tiger). Delivered >2.2M annotated datapoints over 65 targets for training generative drug design models. Datasets yielded significantly superior model performance vs CRO and public data, underpinning clinical candidates progressing in 2025.
  • Intelligent OMICScoreStrategic or Co-development Partner · 1 January 2022Innovate UK-backed project combining AI, machine learning and automated biology for lung cancer drug discovery targeting KRAS signalling pathway. Intelligent OMICS provides in silico target identification; Arctoris runs biological assay validation using automated platform.
  • Medicines Discovery CatapultcoreStrategic or Co-development Partner · 1 January 2022Partner in Innovate UK-backed lung cancer project contributing cheminformatics expertise to identify appropriate chemical tools and leads for newly uncovered targets.
  • IBM ResearchcoreStrategic or Co-development Partner · 1 January 2021Collaboration advancing fully autonomous closed-loop molecular discovery targeting Janus kinase (JAK) proteins. Integrates computational molecular design, automated synthesis, and experimental testing into continuous DMTA cycle. Arctoris' Ulysses platform combined with IBM's automated small molecule synthesis capabilities.
  • MoleculeminorStrategic or Co-development Partner · 1 January 2021Collaboration combining Arctoris' automated laboratory infrastructure with Molecule's open-source software platform for drug intellectual property sharing. Aims to reduce legal and financial barriers in collaborative drug discovery.
  • Insilico MedicinecoreStrategic or Co-development Partner · 1 January 2020Technology partnership for AI-guided drug discovery against COVID-19, spanning target identification and generative chemistry. Insilico's AI capabilities combined with Arctoris' robotic platform for rapid evaluation of novel JAK inhibitors. Partnership extended through BioTarget Cancer Research UK initiative for oncology.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Arctoris competitors and assessment

Company assessment

Direct peers

  • Strateos: Cloud-based automated laboratory platform enabling remote-controlled experiments for drug discovery. Operates a similar partnership model providing automated wet-lab data generation services to biotech and pharma customers.
  • Emerald Cloud Lab: Cloud-controlled, fully automated laboratory facility providing remote experimental execution and data generation services. Directly comparable to Arctoris's Ulysses platform in terms of robotic lab infrastructure and service delivery model.
  • Insilico Medicine: AI-driven drug discovery company combining generative AI with experimental validation. Comparable as a direct customer/partner of Arctoris with overlapping AI drug discovery mission and partnership-based commercial model.

Broad incumbents

  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML for pharma partnerships. Comparable as an AI drug discovery peer, though significantly larger and with in-house automated lab capabilities rather than pure service model.
  • Insitro: Machine learning-driven drug discovery company combining proprietary data generation with ML models for pharma partnerships. Comparable as an AI drug discovery peer with experimental data generation capabilities and pharma partnership model.
  • Benchling: Cloud-based life sciences R&D platform providing informatics and data management for biotech R&D. Adjacent peer providing laboratory informatics infrastructure, though focused on software rather than automated experimental execution.
  • Schrödinger: Computational drug discovery platform combining physics-based simulation with ML for pharma partnerships. Comparable as a technology-enabled drug discovery company serving pharma, though primarily computational rather than experimental automation.

Emerging players

  • LabGenius: Machine learning-driven antibody discovery company using automated laboratory robotics. Comparable as a UK-based ML-driven biotech using automation, though focused specifically on biologics rather than small molecules and services.
  • Culture Biosciences: Cloud-based bioprocess development platform providing automated fermentation and cell culture services. Comparable as a cloud-lab automated services provider, though focused on bioprocess rather than drug discovery.
  • Synthace: Cloud-based laboratory automation platform enabling experimental design and execution for life science R&D. Comparable as a lab automation platform serving biotech R&D, though focused on software infrastructure rather than full-service execution.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Arctoris social profiles

Digital presence

Arctoris compliance and trust

Trust signal

Compliance1 record

Arctoris financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arctoris leadership team

Management profile

Number of profiles

Profiles8 records

Arctoris funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arctoris M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arctoris

What does Arctoris do?

Arctoris operates as a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies. The core offering is delivered through Ulysses®, a fully robotic, cloud-controlled drug discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology, generating precise, reproducible, and AI-ready datasets at industrial scale. Services span from target identification through IND-enabling studies via long-term partnership agreements.

Is Arctoris a public or private company?

Arctoris is a private company. It is classified as venture growth investor backed and is currently operating.

When was Arctoris founded?

Arctoris was founded in 2018. It employs 11 to 50 people.

Where is Arctoris based?

Arctoris is headquartered in Abingdon, United Kingdom, in the Europe region.

How does Arctoris make money?

Three revenue lines are on record. Partnership Research Services are the primary driver. The others are foundation Model Data Generation and bespoke Proprietary Training Datasets.

Who are Arctoris's main competitors?

Direct peers on record are Strateos, Emerald Cloud Lab and Insilico Medicine. Broad incumbents are Recursion Pharmaceuticals, Insitro, Benchling and Schrödinger. Emerging players are LabGenius, Culture Biosciences and Synthace.

Does Arctoris have an API?

No public API is recorded for Arctoris.

What industry is Arctoris in?

Arctoris's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAIAD, Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WikipediaDraft:Thomas Fleming (entrepreneur)Thomas Fleming co-founded Arctoris in 2016 and served as CEO from 2024 until September 2026. He led the company's expansion, including a 9,000 sq ft lab expansion and a partnership with IBM Research. He now leads the OpenImmune Foundation while remaining an adviser to Arctoris.Scispotthe lab of the future unveiled : how technology is transforming scientific discovery in 2026Eli Lilly acquired the Science Studio biology platform from Arctoris, a move that significantly expands Arctoris' robotic drug discovery capabilities by integrating Eli Lilly's autonomous lab technology. This transaction highlights the growing trend of leveraging AI and robotics to automate scientific research and accelerate pharmaceutical development.PharmiWeb.comArctoris announces strategic partnership with Alphabet company, Isomorphic LabsArctoris announced a strategic partnership with Isomorphic Labs at FBLD, with Miles Congreve joining its scientific advisory board. Arctoris will generate protein-ligand datasets via its Ulysses platform to train Isomorphic Labs' AI models for drug design.PharmiWeb.comArctoris acquires Eli Lilly ‘Life Science Studio’ laboratoryArctoris has acquired the majority of Eli Lilly's San Diego-based 'Life Science Studio' laboratory, relocating the facility to its headquarters in Oxford. This acquisition adds significant automated biochemistry and cell biology modules to Arctoris' existing infrastructure, effectively doubling the size of its lab operations. The expanded platform is designed to enhance data generation capacity and reduce R&D project timelines for Arctoris' biotech clients.PR NewswireIBM Research and Arctoris accelerate closed loop drug discovery with AI and CloudIBM Research and Arctoris announced a collaboration to combine their AI and automation platforms for closed-loop drug discovery, marking the first integration of IBM's RXN for Chemistry and RoboRXN synthesis tools with Arctoris's Ulysses automated experimentation platform. The partnership will apply a Design, Make, Test, Analyze (DMTA) cycle where IBM designs and synthesizes novel chemical compounds while Arctoris profiles and evaluates them, with resulting data feeding back to improve generative AI models. This collaboration aims to accelerate the identification of small molecule inhibitors through fully automated, data-driven research, though financial terms were not disclosed and the project remains ongoing.Technology NetworksArctoris Launches Its Expanded Robotic Platform UlyssesArctoris unveiled its expanded robotic platform Ulysses, a next-generation system for automated drug discovery. The company, founded in 2016, aims to accelerate drug discovery through automation, with partnerships announced with Insilico Medicine and Syntekabio. It expects accelerated growth over the next five years.SbrArctoris transforms biotech and pharma industry with automated drug discovery platformArctoris, a biotech startup, offers an automated drug discovery platform that accelerates research and reduces failure rates. The company won the Innovator of the Year award in the Biotech category at the SBR Management Excellence Awards 2020 and has raised $10m from investors. It plans to continue rapid growth in 2021 and beyond.News-MedicalArctoris supports global research efforts to combat COVID-19Arctoris established remotely accessible COVID-19 assays, including biochemical and cellular profiling, to support global research. A project generated over 1 million data points for JAK-family kinases, and a sample-pooling tool could increase testing capacity by eightfold.Labiotech.euDrug Development in Covid-19 Times: Is Going Remote the Answer?European biotechs are developing remote robotic labs to automate drug development, driven by pandemic-induced lab closures. The technology aims to cut costs and reduce human error, with companies like Synthace and Arctoris offering cloud-based platforms. Automation could also lower costs for cell and gene therapies.Science Laboratory Equipment News From Labmate OnlineCombined Technologies Approach could Ease Drug DevelopmentArctoris and Molecule announced a partnership combining Arctoris' automated drug discovery platform with Molecule's distributed IP ownership platform to reduce reproducibility and data quality issues in drug development. The collaboration aims to create an open-source ecosystem with fractional IP ownership and funding for stakeholders, including universities and patient groups.